Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation

Bone

Volumn 36, Issue 2, 2005, Pages 284-291

  Regmi, Ajit ^a   Fuson, Tina ^a   Yang, Xuhao ^a   Kays, Joanne ^a   Moxham, Christopher ^a   Zartler, Edward ^a   Chandrashekhar, Srinivasan ^a   Galvin, Rachelle J Sells ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Osteoclast differentiation; RANK; Suramin

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN KINASE B; RECEPTOR ACTIVATOR OF NK KAPPA B; SURAMIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; CALVARIA; CELL CYCLE; CELL DIFFERENTIATION; CHIMERA; CONTROLLED STUDY; IN VITRO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OSTEOCLAST; OSTEOLYSIS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SPLEEN CELL;

EID: 14144255869     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2004.09.022     Document Type: Article

References (22)

1. R. Alzani, A. Corti, L. Grazioli, E. Cozzi, P. Ghezzi, and F. Marcucci Suramin induces deoligomerization of human tumor necrosis factor-alpha J. Biol. Chem. 268 1993 12526 12529
2. S.J. Dixon, and S.M. Sims P2 purinerigic receptors on osteoblasts and osteoclasts: potential targets for drug development Drug Dev. Res. 49 2000 187 200
3. K.H. Farsoudi, P. Pietschmann, H.S. Cross, and M. Peterlik Suramin is a potent inhibitor of calcemic hormone- and growth factor-induced bone resorption in vitro J. Pharmacol. Exp. Ther. 264 1993 579 583
4. F. Hawking Suramin: with special reference to onchocerciasis Adv. Pharmacol. Chemother. 15 1978 289 322
5. J. Ivey, D. Wright, and A. Tashjian Bone resorption in organ culture: Inhibition by the divalent cation ionophores A23187 and X-537A J. Clin. Invest. 58 1976 1327 1338
6. V. John, J.M. Hock, L.L. Short, A.L. Glasebrook, and R.J.S. Galvin A role for CD8(+) T-lymphocytes in osteoclast differentiation in vitro Endocrinology 137 1996 2457 2463
7. P. Kloen, C.L. Jennings, M.C. Gebhardt, D.S. Springfield, and H.J. Mankin Suramin inhibits growth and transforming growth factor-β1 (TGF-β1) binding in osteosarcoma cell lines Eur. J. Cancer 30A 1994 678 682
8. R. Kopp, and A. Pfeiffer Suramin alters phosphoinositide synthesis and inhibits growth factor receptor binding in HT-29 cells Cancer Res. 50 1990 6490 6496
9. X. Li, N. Udagawa, K. Itoh, K. Suda, Y. Murase, and T. Nishihara p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function Endocrinology 143 2002 3105 3113
10. F. Mancini, C.M. Toro, M. Mabilia, M. Giannangeli, M. Pinza, and C. Milanese Inhibition of tumor necrosis factor-α (TNF-α)/TNF-α receptor binding by structural analogues of suramin Biochem. Pharmacol. 58 1999 851 859
11. M. Matsumoto, T. Sudo, T. Saito, H. Osada, and M. Tsujimoto Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-κB ligand (RANKL) J. Biol. Chem. 275 2000 31155 31161
12. M. Mayer, and B. Meyer Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor J. Am. Chem. Soc. 123 2001 6108 6117
13. C.R. Middaugh, H. Mach, C.J. Burke, D.B. Volkin, J.M. Dabora, and P.K. Tsai Nature of the interaction of growth factors with suramin Biochemistry 31 1992 9016 9024
14. V. Sklenar, M. Piotto, R. Leppik, and V. Saudek Gradient-tailored water suppression for 1h-15n hsqc experiments optimized to retain full sensitivity J. Magn. Reson., Ser. A 102 1993 241 245
15. C.A. Stein Suramin: a novel antineoplastic agent with multiple potential mechanisms of action Cancer Res. 53 1993 2239 2248
16. T. Suda, N. Takahashi, N. Udagawa, E. Jimi, M. Gillespie, and T. Martin Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families Endocr. Rev. 20 1999 345 357
17. S. Teitelbaum Bone resorption by osteoclasts Science 289 2000 1504 1508
18. R.J. Thomas, T.A. Guise, J.J. Yin, J. Elliott, N.J. Horwood, and T.J. Martin Breast cancer cells interact with osteoblasts to support osteoclast formation Endocrinology 140 1999 4451 4458
19. M.M. Walther, P.J. Kragel, E. Trahan, D. Venzon, H.C. Blair, and P.H. Schlesinger Suramin inhibits bone resorption and reduces osteoblast number in a neonatal mouse calvarial bone resorption assay Endocrinology 131 1992 2263 2270
20. S. Wei, M.W. Wang, S.L. Teitelbaum, and F.P. Ross Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-κB and mitogen-activated protein kinase signaling J. Biol. Chem. 277 2002 6622 6630
21. B.R. Wong, D. Besser, N. Kim, J.R. Arron, M. Vologodskaia, and H. Hanafusa Trance, a TNF family member, activates AKT/PKB through a signaling complex involving TRAF6 and c-src Mol. Cell 4 1999 1041 1049
22. T. Yoneda, P. Williams, C. Rhine, B. Boyce, C. Dunstan, and G. Mundy Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer Cancer Res. 55 1995 1989 1993